The GSK share price is beating the FTSE 100: should you keep buying?

The GSK share price looks cheap compared to rivals, says Roland Head. He explains why he thinks this business could be undervalued at current levels.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharma giant GlaxoSmithKline (LSE: GSK) is ahead of the FTSE 100 so far this year. The GSK share price is down by a mere 6% or so, compared with a drop of more than 20% for the big-cap index.

Of course, most pharmaceutical stocks have done well during the coronavirus pandemic. Some have performed much better than Glaxo. However, I think that some of these high flyers are starting to look expensive. In my view, Brentford-based GSK now offers much better value than most rivals.

Why is GSK cheaper?

The group’s near-term growth prospects aren’t quite as exciting as those of rival AstraZeneca. Although one-off gains from stockpiling and acquisitions helped to lift GlaxoSmithKline’s sales by 19% during the first quarter, the outlook for full-year earnings is broadly unchanged this year.

By contrast, AstraZeneca expects to report a “mid-to-high teens percentage” increase in adjusted earnings this year.

Investors have chased Astra shares to record levels. But I think the good news is already in the price. I expect Glaxo’s growth rate to improve over the coming years. In my view, this is the better share to be buying today.

Will coronavirus vaccine boost GSK shares?

Many small pharmaceutical stocks have rocketed on hopes that they might discover a coronavirus vaccine. The GSK share price has stayed steady, even though Glaxo is working on a coronavirus vaccine too. But the company isn’t gambling everything on this. Instead, it’s taking a measured approach to creating treatments that could be used to manage the current pandemic and future, similar, viruses.

Even if Glaxo succeeds, a coronavirus vaccine would be just one product in its portfolio of vaccines, cancer treatments and other medicines. Alongside this, the company also has a strong set of consumer healthcare products, including brands such as Sensodyne and Aquafresh.

The diversity of this business suits me just fine — I don’t want to own all-or-nothing stocks. I want reliable performers that can chuck out growing profits and dividends, year after year. I believe Glaxo fits the bill perfectly.

I think the GSK share price is too cheap

I already own a reasonable chunk of GlaxoSmithKline stock, but I think the stock offers good value at current levels and I’m planning to buy more.

One reason for this is simply that I think the shares are quite reasonably priced. At the time of writing, GSK shares are trading at about 1,670p. This price puts the stock on a forecast price/earnings ratio of less than 15, with a dividend yield of around 4.7%.

That works for me, especially as AstraZeneca is currently trading on 27 times 2020 forecast earnings, with a dividend yield of just 2.6%. In my view, AZN’s stronger growth outlook is not enough to justify such a steep valuation.

Split could lift shares

There’s also a second reason why I’m buying GSK stock. The company is planning to spin out its newly-enlarged consumer healthcare business into a separate listing in 2021. Shareholders will receive shares in the new company.

I’m pretty keen on this. I think the split should create two more efficient businesses with good long-term growth prospects. In my view, both halves of GSK are likely to attract higher valuations as standalone businesses. In the meantime, shareholders get a tasty 4.7% dividend yield. That’s why I’m building up my shareholding before the split.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Would it be pure madness to pile into the S&P 500?

The S&P 500 is currently in the midst of a skyrocketing bull market, but valuations are stretched. Is there danger…

Read more »

Investing Articles

If I’d put £20k into the FTSE 250 1 year ago, here’s what I’d have today!

The FTSE 250 has outperformed the bigger FTSE 100 over the last year. Roland Head highlights a mid-cap share to…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Growth Shares

The Scottish Mortgage share price is smashing the FTSE 100 again

Year to date, the Scottish Mortgage share price has risen far more than the Footsie has. Edward Sheldon expects this…

Read more »

Investing Articles

As H1 results lift the Land Securities share price, should I buy?

An improving full-year outlook could give the Land Securities share price a boost. But economic pressures on REITs are still…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

How much are Rolls-Royce shares really worth as we approach 2025?

After starting the year at 300p, Rolls-Royce shares have climbed to 540p. But are they really worth that much? Edward…

Read more »

Investing Articles

Despite rocketing 33% this hidden FTSE 100 gem is still dirt cheap with a P/E under 5!

Harvey Jones has been tracking this under -the-radar FTSE 100 growth stock for some time. He thinks it looks a…

Read more »

Dividend Shares

How I could earn a juicy second income starting with just £250

Jon Smith explains how investing a regular amount each month in dividend stocks with above average yields can build a…

Read more »

Young female hand showing five fingers.
Investing Articles

If I’d put £10,000 into the FTSE 250 5 years ago, here’s how much I’d have now!

The FTSE 250 hasn’t done well over the past five years. But by being selective about which of its stocks…

Read more »